Sotera Health Company research snapshot
SHC AI stock analysis currently reads Sotera Health Company as an essential medical sterilization services provider with a resilient business model. The page uses a scenario framework, not a certain price prediction. At the July 12, 2026 cutoff, the quoted price was $18.02, market capitalization was about $5.14 billion, and the main decision point was whether the company can sustain growth while managing the Ethylene Oxide (EtO) regulatory and litigation overhang. This is informational research and not investment advice.
Current price
$18.02
Market cap
$5.14 billion
AI score
58 / 100
Rating
Resilient business franchise with regulatory overhang
Trend status
Medium-term uptrend with elevated volatility from regulatory headlines
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Sotera Health provides outsourced sterilization services that medical device and pharmaceutical products require before patient use. Demand is non-discretionary and regulated. | Medium-high |
| Moat | The moat combines regulatory barriers, customer revalidation costs, facility network density, and Cobalt-60 supply chain position. However, EtO litigation has created a reputation and regulatory cost that partially offsets these advantages. | Medium |
| Management | Management has been navigating the EtO regulatory environment and diversifying into alternative technologies. Capital allocation discipline and litigation reserve strategy are key monitoring points. | Medium |
| Financial trend | Price, shares, market cap, revenue, net income, and cash were mechanically verified. Debt level is elevated with 365% D/E ratio, requiring monitoring of interest coverage and refinancing risk. | Medium-high |
| Valuation | At 44x TTM P/E, valuation is elevated on current earnings, but forward P/E of 18x implies significant earnings growth. EV/EBITDA of 14.7x is reasonable for an essential-service business with recurring revenue characteristics. | Medium-low |
| Technical trend | Medium-term uptrend with price near the upper end of a 52-week range. Use live moving averages, support, resistance, momentum, volume, and invalidation levels before acting. | Medium |
| Risk level | The thesis can fail if EtO regulations tighten significantly, litigation costs escalate, facility permits are revoked, or technology shifts reduce sterilization demand. High debt amplifies downside outcomes. | Medium-high |
| AI confidence | Medium-high data confidence for financial statement data and market pricing. Lower confidence for forward returns given the regulatory binary risk profile. | Medium-high data confidence |
| Investment certainty | Low-medium certainty because the page gives a framework, not a personalized buy or sell instruction, and the regulatory risk path is inherently uncertain. | Low-medium |
SHC AI stock forecast
The SHC AI stock forecast uses scenario ranges around the $18.02 quote rather than a point target. The bullish case requires evidence that EtO regulatory risk is contained and demand growth continues; the base case assumes mixed execution with manageable litigation; the bearish case assumes regulatory or legal outcomes materially impair the business model.
$22.00 to $26.50
More likely if Sotera Health shows strengthening revenue growth from alternative sterilization technologies (X-ray, e-beam), litigation reserves prove adequate, and the stock reclaims resistance with sustained volume on favorable regulatory developments.
$15.50 to $21.00
More likely if fundamentals remain mixed and the stock trades around current expectations while investors monitor Q2 2026 earnings and EtO regulatory updates.
$9.00 to $14.00
More likely if these risk paths appear: adverse EtO regulation or facility closure orders, litigation costs materially exceeding reserves, debt covenant pressure, or technical support breaks decisively after the data cutoff.
SHC AI technical analysis
SHC AI technical analysis starts from the $18.02 quote. Because this static page does not fetch request-time chart data, moving averages and live momentum should be confirmed in a charting tool before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $18.02 | Current quote used for this page as of the July 12, 2026 data cutoff. |
| Near support | $15.80 to $16.80 | Estimated from the 52-week range and recent price action. Treat as a planning zone, not a guaranteed floor. |
| Near resistance | $19.85 to $21.00 | The upper end of the 52-week range at $19.85 is the first major resistance. A close above this zone would signal a new high and improved momentum. |
| 50-day moving average | Requires live chart confirmation | Use current chart data before acting. The page does not fetch request-time market data. |
| 200-day moving average | Requires live chart confirmation | Long-term trend confirmation should be checked against a live chart or broker data. |
| Momentum | Medium-term uptrend with headline-driven volatility | Price action around the $18 area should be confirmed with volume and regulatory news flow. |
| Volume | Average daily volume approximately 3.2 million shares | Trading volume can spike significantly on EtO regulatory news or earnings releases. |
| Volatility | Elevated monitoring priority | Beta of 1.77 indicates the stock moves more than the broad market. Use position sizing that can tolerate wide daily movement. |
| Invalidation | Close below $15.80 | A decisive close below the support zone with elevated volume would weaken the medium-term setup. |
SHC AI trading strategy
The SHC AI trading strategy is a rules-based research framework. It is not personalized advice and should be paired with position sizing, stop levels, and fresh filings or news checks before execution.
Wait for SHC to hold above near support and push through the resistance zone near $19.85 with volume that confirms buyer demand and favorable regulatory news.
A close below the support zone or a failed breakout should invalidate the setup. Monitor EtO regulatory headlines closely.
If SHC falls into the support band without a thesis-breaking regulatory event, compare price action with the next earnings, balance sheet, and litigation reserve disclosures.
Do not average down without a predefined maximum loss and a fresh review of the business and regulatory risk.
Track the evidence that matters most for Sotera Health: sterilization volume trends, alternative technology revenue mix, litigation reserve adequacy, debt metrics, and regulatory developments across key facilities.
Reduce confidence when price moves are driven by litigation headlines without matching fundamental evidence. The high debt load requires monitoring of interest coverage ratios.
Investment research summary
Sotera Health provides outsourced sterilization services that medical device and pharmaceutical products require before they can be used on patients. The company operates through three segments: Sterigenics (contract sterilization), Nordion (Cobalt-60 supply), and Nelson Labs (lab testing).
The moat combines regulatory barriers to entry, customer revalidation costs that create switching friction, facility network density, and Nordion position in the Cobalt-60 supply chain. The EtO litigation has partially eroded this moat by creating regulatory and reputation costs.
The thesis can fail if EtO regulations tighten materially, litigation costs escalate beyond reserves, facility operating permits are revoked or restricted, alternative sterilization technologies disrupt demand, or the high debt burden causes financial distress during adverse scenarios.
Management has prioritized navigating the regulatory environment, investing in alternative sterilization technologies (X-ray, e-beam), and refinancing debt at better terms. The capital allocation strategy and litigation reserve decisions are key monitoring points.
Medical device sterilization is a secular growth market driven by aging populations, expanding healthcare access, and increasing medical procedures. However, the regulatory environment for EtO sterilization is under active scrutiny, creating uncertainty for a key sterilization method.
At 44x TTM P/E and 14.7x EV/EBITDA, valuation prices in substantial earnings growth and resolution of regulatory overhang. Safety margin is thin if growth disappoints or litigation costs escalate. Forward P/E of 18x reflects expected earnings normalization.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| SHC price | $18.02 | Current quote snapshot cross-checked with user supplied market scan | July 12, 2026 |
| Market capitalization | $5.14 billion, verified as $18.02 x 285.2 million shares via financial_rigor.py | financial_rigor.py market cap verification | July 12, 2026 |
| Enterprise value | $7.07 billion | Yahoo Finance key statistics | July 12, 2026 |
| Revenue (TTM) | $1.19 billion | Yahoo Finance financial summary | July 12, 2026 |
| Net income (TTM) | $117.79 million | Yahoo Finance financial summary | July 12, 2026 |
| EPS (TTM) | $0.41 | Yahoo Finance statistics | July 12, 2026 |
| Free cash flow (TTM) | $144.78 million | Yahoo Finance statistics | July 12, 2026 |
| Cash and equivalents | $314.36 million | Yahoo Finance balance sheet summary | July 12, 2026 |
| Debt to equity | 364.72% | Yahoo Finance statistics | July 12, 2026 |
| Exchange | NasdaqGS | User supplied market scan and public quote pages | July 12, 2026 |
| 52-week range | $10.94 to $19.85 | Yahoo Finance statistics | July 12, 2026 |
| Financial statement depth | Public filings available on SEC EDGAR. Two-source statement checks still recommended before investment use. | Research quality check | July 12, 2026 |
This SHC AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of July 12, 2026, may be incomplete, and can be wrong if new filings, market prices, company events, or macro conditions change. The EtO regulatory and litigation environment creates inherent uncertainty that cannot be modeled with precision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
